Research
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
-
* Corresponding author: Joseph M Tuscano joseph.tuscano@ucdmc.ucdavis.edu
Journal of Hematology & Oncology 2011, 4:49 doi:10.1186/1756-8722-4-49
No comments have yet been made on this article.